Correlative Study of Tumor Hypoxia and Metastatic Potential in Breast Cancer.

Abstract

We propose a novel physiological approach using tumor hypoxia assessment to study the metastatic potential of primary breast cancer cells. Does the presence of hypoxia in breast primary detected by pimonidazole immunohistochemical binding, correlate with the presence of axillary lymph node metastases, and correlate the presence of hypoxia with markers of cell proliferation, p53, apoptosis, and VEGF in the primary breast tumor tissue. The specific aims are: (1) Determine the presence and extent of tumor hypoxia in biopsies of primary breast cancer using pimonidazole binding to hypoxic tumor cells. (2) Determine the patterns of pimonidazole binding in the breast cancer biopsies in relation to other landmarks such as blood vessels and necrosis. (3) Correlate the presence and extent of tumor hypoxia in primary breast cancer with the presence of axillary node metastases. (4) Correlate the presence and extent of tumor hypoxia with the presence of other biological markers: p53, apoptosis, PCNA, Ki-67, and VEGF. (5) Monitor adverse effects of pimonidazole. The clinical protocol has not been initiated. Please see the Annual Report Statement. We request deferral of the start date of the clinical research protocol to November 1st, 1998 or earlier pending Review Committee approval.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 1998
Accession Number
ADA357252

Entities

People

  • Mahesh A. Varia

Organizations

  • University of North Carolina at Chapel Hill

Tags

DTIC Thesaurus Topics

  • Apoptosis
  • Biological Markers
  • Biomedical Research
  • Blood
  • Blood Vessels
  • Breast Cancer
  • Department Of Defense
  • Federal Law
  • Laboratory Animals
  • Law
  • Lymph Nodes
  • Lymphatic System
  • Materials
  • Neoplasms
  • North Carolina
  • Radiation Oncology
  • Recombinant Dna

Fields of Study

  • Biology

Readers

  • Cardiovascular Physiology
  • Molecular Biology and Genetics
  • Oncology and Biomarker-Based Cancer Detection.